Cipla Ltd.

Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, (‘Listing Regulations’), Cipla has informed that the Company has entered into a marketing and distribution agreement with Eli Lilly and Company (India) (referred as ‘Lilly’) for launch of second brand of Tirzepatide in India. The details required to be disclosed under the Listing Regulations read with SEBI Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November, 2024 on Lilly and Cipla sign marketing and distribution agreement for second brand of Tirzepatide in India are enclosed to this intimation as Annexure I. A copy of the press release pertaining to the said product launch is enclosed as Annexure II.